Clinical trials: Inpatients
Post-Operative Pain
A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain
The study is intended to show that the Sufentanil NanoTab PCA System is as effective as morphine intravenous patient-controlled analgesia (IV PCA) for treating pain after surgery.
- Trial name
- NCT01539538
- Testing
- Sufentanil NanoTab PCA System/15 mcg, morphine IV PCA
- Where
- 16 sites in United States
- Volunteers
- 357 people
- Sponsor
- Talphera, Inc
Hernioplasty
Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant
Assess the pharmacokinetic profile of 2 doses of the XaraColl® implant after open laparotomy hernioplasty and assess the relative bioavailability of Xaracoll compared to a local bupivacaine infiltration.
- Trial name
- NCT02232178
- Testing
- 2 100mg Xaracoll implants, 3 100mg Xaracoll implants, 150mg Bupivacaine HCl injection
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Innocoll
Pain, Fever
Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients
We are doing this study to find out what happens to acetaminophen in the body after it is given to children through the vein. Children's bodies may handle drugs differently than adults.
- Trial name
- NCT00493246
- Testing
- IV Acetaminophen
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Mallinckrodt
Epilepsy
Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern
This is a multi-center, double-blind, randomized, parallel group, dose-ranging study to investigate the efficacy and clinical usability of STAP-001 in adult (18 years of age and older) subjects with epilepsy with a predictable…
- Trial name
- StATES (NCT03478982)
- Testing
- Staccato Alprazolam
- Where
- 67 sites in United States, Australia and 1 more
- Volunteers
- 156 people
- Sponsor
- Engage Therapeutics, Inc.
Bipolar Depression
Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression
The purpose of the study is to compare the sedation profile one hour after dose administration between Seroquel IR and Seroquel XR.
- Trial name
- NCT00926393
- Testing
- Quetiapine Immediate Release, Quetiapine Extended Release
- Volunteers
- 139 people
- Sponsor
- AstraZeneca
Schizophrenia
Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo
To assess the efficacy and safety of an investigational compound PF-02545920 for the treatment of schizophrenia. PF-02545920 will be more effective than placebo in reducing symptoms associated with schizophrenia.
- Trial name
- NCT00570063
- Testing
- PF-02545920
- Where
- 10 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pfizer
Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Hypothesis: 3,4-Diaminopyridine base (3,4-DAP) improves Lambert-Eaton Myasthenic Syndrome (LEMS)-related weakness.
- Trial name
- DAPPER (NCT01511978)
- Testing
- Continuous 3,4-DAP
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Jacobus Pharmaceutical
Opioid Use Disorder
Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.
- Trial name
- NCT05924945
- Testing
- Bridge™ active device
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masimo Corporation
In-Hospital Cardiac Arrest
Hospital Wearable Defibrillator Inpatient Study
This study will obtain device-human interaction evaluations for the HWD1000 within the controlled environment of the hospital as well as establish that the safety profile is similar to outpatient wearable…
- Trial name
- HWD (NCT02122549)
- Testing
- HWD1000
- Where
- 8 sites in United States
- Volunteers
- 59 people
- Sponsor
- Zoll Medical Corporation
Pain, Fever
Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients
Intravenous acetaminophen (IVAPAP) is safe in repeated dose, multi-day clinical use when administered at a daily dose of 40 to 75 mg/kg body weight
- Trial name
- NCT00598702
- Testing
- IV Acetaminophen
- Where
- 14 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mallinckrodt
Staphylococcal Skin Infections
Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
This was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin.
- Trial name
- DAPHEOR1006 (NCT01419184)
- Testing
- Daptomycin, Vancomycin
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Gram-Positive Infections
A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)
The primary objectives of this study are to describe the single-dose, and multiple dose pharmacokinetics (PK) of intravenous (IV) tedizolid phosphate, or a single dose oral suspension of tedizolid phosphate, when administered to…
- Trial name
- NCT03217565
- Testing
- IV Tedizolid Phosphate, Oral Suspension Tedizolid Phosphate
- Where
- 30 sites in United States, Bulgaria and 3 more
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes
An Inpatient Evaluation of Six-Day Subcutaneous Glucose Sensor Performance
The purpose of this study is to assess the performance of the subcutaneous glucose sensor over an extended sensor life. The sensor is currently approved for 3 days of use and this study will examine sensor safety and accuracy…
- Trial name
- 6-DayFU (NCT00865345)
- Testing
- MMT-7003 subcutaneous glucose sensor
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Medtronic MiniMed, Inc.
Wound Debridement
Chitosan Dressings to Facilitate Safe Effective Debridement of Chronic Wounds & Minimize Wound Bacterial Re-colonization
The purpose of this study is to determine if the use of HemCon chitosan-based dressings is effective to facilitate safe, effective debridement of chronic wounds in the operating room and inpatient ward settings and to minimize…
- Trial name
- NCT01035944
- Testing
- HemCon Dressings and HemCon ChitoGauze; chitosan-based., Gauze and saline dressings.
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- HemCon Medical Technologies, Inc
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor
The purpose of the study is to assess the performance of a new subcutaneous glucose sensor over a seven-day sensor life when used with currently marketed Medtronic Diabetes devices.
- Trial name
- NCT01112696
- Testing
- Sensor wear
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
The aim of this study is to evaluate safety and efficacy of therapy with saxagliptin 5mg co-administered with dapagliflozin 5mg, compared to therapy with saxagliptin 5mg or dapagliflozin 5mg in patients who are inadequately…
- Trial name
- NCT02681094
- Testing
- Dapagliflozin, Saxagliptin
- Where
- 110 sites in United States, Canada and 4 more
- Volunteers
- 905 people
- Sponsor
- AstraZeneca
Schizophrenia
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period.
- Trial name
- NCT01175135
- Testing
- PF-02545920, Risperidone
- Where
- 46 sites in United States, Germany and 1 more
- Volunteers
- 259 people
- Sponsor
- Pfizer
Chronic Myeloid Leukemia
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
To satisfy a postmarketing requirement, the sponsor has been requested to conduct a Phase 1/Phase 2 single-group clinical study to investigate the pharmacokinetics and preliminary safety and efficacy of omacetaxine following a…
- Trial name
- NCT02078960
- Testing
- Omacetaxine mepesuccinate
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 10 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Diabetes Mellitus, Type 2
A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes
This will be a 2-week oral dose study of PF 04991532, performed in patients with type 2 diabetes. Safety, pharmacokinetics (how the drug is distributed in the body), and pharmacodynamics (how the drug works in the body) will be…
- Trial name
- NCT01469065
- Testing
- PF-04991532, PF-0499132
- Where
- 3 sites in United States, Japan
- Volunteers
- 82 people
- Sponsor
- Pfizer
Acute Pain, Fever
Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients
The study will be investigating safety and efficacy administration of repeated dose of IV Acetaminophen (IV APAP) over five days for the treatment of acute pain or fever in adult patients.
- Trial name
- NCT00598559
- Testing
- IV Acetaminophen
- Where
- 14 sites in United States
- Volunteers
- 213 people
- Sponsor
- Mallinckrodt